Price$2.98+1.78 (+148.75%)
2026-05-212026-08-25
News · 26 weeks74-36%
2026-03-012026-08-23
Mix3090d
- Insider13(43%)
- SEC Filings7(23%)
- Other6(20%)
- Leadership2(7%)
- Analyst1(3%)
- Earnings1(3%)
Latest news
25 items- SECSEC Form 8-K filed by Neuronetics Inc.8-K - Neuronetics, Inc. (0001227636) (Filer)
- INSIDERLarge owner Chernett Jorey bought $44,240 worth of shares (14,000 units at $3.16), increasing direct ownership by 0.13% to 10,602,988 units (SEC Form 4)4 - Neuronetics, Inc. (0001227636) (Issuer)
- SECSEC Form S-8 filed by Neuronetics Inc.S-8 - Neuronetics, Inc. (0001227636) (Filer)
- SECSEC Form 10-Q filed by Neuronetics Inc.10-Q - Neuronetics, Inc. (0001227636) (Filer)
- SECNeuronetics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure8-K - Neuronetics, Inc. (0001227636) (Filer)
- PRNeuronetics Reports Second Quarter 2026 Financial and Operating ResultsMALVERN, Pa., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company" or "Neuronetics"), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced its financial and operating results for the second quarter of 2026. Second Quarter 2026 Financial Highlights Total revenue of $41.6 million, up 9.1% compared to the second quarter of 2025Greenbrook revenue of $26.9 million, up 16.8% compared to the second quarter of 2025Adjusted EBITDA of $0.3 million compared to a loss of $5.6 million in the second quarter of 2025 Net loss of $3.4 m
- PRNeuronetics and Jorey Chernett Announce Shared VisionChernett Affirms Comfort with the Company’s Capital Position and Confidence in Management’s ExecutionEstablishes Path Towards Neuronetics Board Representation MALVERN, Pa., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) ("Neuronetics" or the "Company") and Jorey Chernett, the Company’s second largest shareholder and Managing Member of Pointillist Family Office, today announced that they have created a constructive framework for alignment between the Company’s Board of Directors (the "Board"), management, and Mr. Chernett (the "Understanding"). The Understanding confirms the Board’s commitment to maximizing shareholder value. The Board will continue to regularly evaluat
- PRNeuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)MALVERN, Pa., July 31, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced the granting of inducement awards to five new non-executive employees as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics’ Compensation Committee and made as a material inducement to their respective employment with the Company. In all cases, vesting is subject to the recipient’s continued service with the Company through the applicable vesting date, and the
- PRGreenbrook Opens National Center of Excellence for Advanced Interventional Psychiatry in Rockville, MarylandMALVERN, Pa., July 28, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced the grand opening of Greenbrook Mental Wellness Centers’ National Center of Excellence in Rockville, Maryland. Overseen by Neuronetics’ Chief Medical Officer Geoffrey Grammer, M.D., the nearly 7,000-square-foot facility is the largest Greenbrook center to date and reflects a significant investment in the future of interventional psychiatry, serving as a national blueprint for advanced, patient-centered mental health ca
- PRNeuronetics to Report Second Quarter 2026 Financial and Operating Results and Host Conference CallMALVERN, Pa., July 28, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced that it plans to release second quarter 2026 financial and operating results prior to market open on Tuesday, August 11, 2026. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/7ri4xna9. To listen to the conference call on your telephone, participants may
- INSIDEREVP, CFO & Treasurer Naor Nir was granted 500,000 shares (SEC Form 4)4 - Neuronetics, Inc. (0001227636) (Issuer)
- INSIDERSEC Form 3 filed by new insider Naor Nir3 - Neuronetics, Inc. (0001227636) (Issuer)
- SECNeuronetics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Neuronetics, Inc. (0001227636) (Filer)
- PRNeuronetics Appoints Nir Naor Chief Financial Officer; Announces Additional Management ChangesNir Naor appointed Chief Financial Officer effective July 23, 2026, bringing more than 20 years of finance and life sciences experienceCory Anderson promoted to Executive Vice President and General Manager, Greenbrook effective July 1, 2026Andrew Macan to step down as Executive Vice President, Chief Legal Officer & Corporate Secretary, effective August 15, 2026 MALVERN, Pa., July 20, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced that Nir Naor will be appointed Chief Financial Officer e
- ANALYSTBTIG Research initiated coverage on Neuronetics with a new price targetBTIG Research initiated coverage of Neuronetics with a rating of Buy and set a new price target of $5.00
- INSIDERLarge owner Chernett Jorey bought $62,300 worth of shares (35,000 units at $1.78), increasing direct ownership by 0.33% to 10,588,988 units (SEC Form 4)4 - Neuronetics, Inc. (0001227636) (Issuer)
- INSIDERNew insider Anderson Cory claimed ownership of 416,812 shares (SEC Form 3)3 - Neuronetics, Inc. (0001227636) (Issuer)
- PRNeuronetics to Participate in a Panel Discussion at B. Riley Securities' Mind, Muscle & Vision Summit on July 16, 2026MALVERN, Pa., July 06, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced that management will participate at the B. Riley Securities' Mind, Muscle & Vision Summit, an invitation-only institutional investor event being held in-person at the InterContinental Boston.Neuronetics will participate in a panel discussion titled "Commercializing the Next Wave of Novel Neuropsychiatric Drugs," alongside Compass Pathways, scheduled for Thursday, July 16, 2026. Management will also be available for one
- SECSEC Form 8-K filed by Neuronetics Inc.8-K - Neuronetics, Inc. (0001227636) (Filer)
- INSIDERDirector Amin Avinash disposed of 42,500 shares, decreasing direct ownership by 59% to 30,000 units (SEC Form 4)4 - Neuronetics, Inc. (0001227636) (Issuer)
- INSIDERLarge owner Madryn Asset Management, Lp acquired 72,500 shares (SEC Form 4)4 - Neuronetics, Inc. (0001227636) (Issuer)
- PRNeuronetics Appoints Robert Greene as Senior Vice President SalesMALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today announced that Robert Greene has been appointed as the company's Senior Vice President Sales, effective June 1, 2026. Rob brings extensive experience leading commercial strategy and sales organizations within healthcare and medical technology, including capital equipment and service. Inducement Grant under Nasdaq Listing Rule 5635(c)(4) In connection with his hiring on June 1, 2026, the Co
- SECSEC Form SD filed by Neuronetics Inc.SD - Neuronetics, Inc. (0001227636) (Filer)
- INSIDERDirector Rosengarten Megan was granted 30,000 shares, increasing direct ownership by 21% to 170,890 units (SEC Form 4)4 - Neuronetics, Inc. (0001227636) (Issuer)
- INSIDERDirector Muir Glenn P was granted 30,000 shares, increasing direct ownership by 8% to 401,816 units (SEC Form 4)4 - Neuronetics, Inc. (0001227636) (Issuer)
STIM FAQ
7 questionsWhat does Neuronetics Inc. do?
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company...Where does STIM stock trade?
Neuronetics Inc. (STIM) is listed on NASDAQ.What sector and industry is STIM in?
Neuronetics Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Neuronetics Inc. go public?
Neuronetics Inc. (STIM) completed its IPO in 2018.What are analysts saying about STIM?
Neuronetics Inc. has had 5 recent analyst actions on file. The most recent action was from BTIG Research: Buy with a $500.00 price target on 2026-07-20. Recent price targets range from $500.00 to $1200.00.What companies are similar to STIM?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare STIM side-by-side with any of them on Quantisnow.How can I track STIM on Quantisnow?
Quantisnow aggregates Neuronetics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow STIM to receive live email and push alerts on every new disclosure.